RT Journal Article
T1 Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics.
A1 Martín-Blázquez, Ariadna
A1 Jiménez-Luna, Cristina
A1 Díaz, Caridad
A1 Martínez-Galán, Joaquina
A1 Prados, Jose
A1 Vicente, Francisca
A1 Melguizo, Consolación
A1 Genilloud, Olga
A1 Pérez Del Palacio, José
A1 Caba, Octavio
K1 biomarker
K1 diagnosis
K1 metabolomics
K1 pancreatic ductal adenocarcinoma
K1 reverse-phase liquid chromatography
AB Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal cancers, with a 5-year survival rate of less than 5%. In fact, complete surgical resection remains the only curative treatment. However, fewer than 20% of patients are candidates for surgery at the time of presentation. Hence, there is a critical need to identify diagnostic biomarkers with potential clinical utility in this pathology. In this context, metabolomics could be a powerful tool to search for new robust biomarkers. Comparative metabolomic profiling was performed in serum samples from 59 unresectable PDAC patients and 60 healthy controls. Samples were analyzed by using an untargeted metabolomics workflow based on liquid chromatography, coupled to high-resolution mass spectrometry in positive and negative electrospray ionization modes. Univariate and multivariate analysis allowed the identification of potential candidates that were significantly altered in PDAC patients. A panel of nine candidates yielded excellent diagnostic capacities. Pathway analysis revealed four altered pathways in our patients. This study shows the potential of liquid chromatography coupled to high-resolution mass spectrometry as a diagnostic tool for PDAC. Furthermore, it identified novel robust biomarkers with excellent diagnostic capacities.
SN 2072-6694
YR 2020
FD 2020-04-18
LK https://hdl.handle.net/10668/28183
UL https://hdl.handle.net/10668/28183
LA en
DS RISalud
RD Apr 6, 2025